RxDoctor Payments DataLook up a doctor →

David Weisman, MD

Neurology · Abington, PANPI 1295832723

Payments from drug & device makers

$9,281,706in general payments, 2019–2025

Across 1,293 payments — averaging $7178.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$3.1M
  • Eli Lilly$2M
  • Novartis$1.6M
  • Eisai Inc.$934K
  • Biogen$615K
  • F. Hoffmann-la Roche AG$365K
  • plus $680K from 54 others
$3,405in research payments, 2019–2025

Across 7 payments — averaging $486.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.161$3,108,392
Eli Lilly62$2,002,961
Novartis38$1,576,846
Eisai Inc.455$934,257
Biogen37$614,819
F. Hoffmann-la Roche AG56$364,675
Alnylam Pharmaceuticals Inc.55$241,597
Acadia Pharmaceuticals Inc51$124,331
Sanofi16$72,394
Lilly USA, LLC74$66,007
Sage Therapeutics, LLC2$62,524
EMD Serono, Inc.39$37,701
Biohaven Pharmaceuticals, Inc.2$19,940
GRT US Holding, Inc.2$18,025
Roche Products Limited30$15,803
Merck14$7,612
AbbVie(2 entities)25$4,427
Avanir Pharmaceuticals, Inc.5$3,287
Osmotica Pharmaceutical Corp.1$2,125
Argenx US, Inc.27$758
Jazz Pharmaceuticals Inc.8$250
Lundbeck LLC14$239
Genentech USA, Inc.9$218
Akcea Therapeutics, Inc.3$216
AstraZeneca(2 entities)9$182
Teva Pharmaceuticals USA, Inc.11$179
SK Life Science, Inc.7$165
TG Therapeutics, Inc.2$156
Roche Diagnostics Corporation2$124
Tanabe Pharma America, Inc.5$114
Sumitomo Pharma America, Inc.6$107
UCB, Inc.5$101
Aucta Pharmaceuticals, Inc.4$97
CSL Behring4$86
Otsuka America Pharmaceutical, Inc.4$76
Takeda Pharmaceuticals U.S.A., Inc.2$75
Grifols USA, LLC4$73
Neurelis, Inc.4$69
Currax Pharmaceuticals LLC4$67
Merz Pharmaceuticals, LLC3$64
Abbott2$40
MDD US Operations, LLC2$39
Avion Pharmaceuticals2$38
Adamas Pharmaceuticals, Inc.2$36
Impel Pharmaceuticals LLC2$34
Pfizer2$33
Harmony Biosciences LLC1$32
Axsome Therapeutics, Inc.2$32
Amgen1$30
Hoffmann-la Roche Limited1$25
Johnson & Johnson1$25
Ipsen Biopharmaceuticals, Inc1$21
Neurocrine Biosciences, Inc.1$21
Inspire Medical Systems, Inc.1$19
Supernus Pharmaceuticals, Inc.1$17
Impel Pharmaceuticals Inc.1$17
Metacel Pharmaceuticals LLC1$16
Mallinckrodt Enterprises LLC1$16
GE HealthCare1$15
Amneal Pharmaceuticals LLC1$14

How this compares

$9,281,706 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$717,232
Medicare patients
673
Services billed
279,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Abington

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →